Rybelsus is a once-daily oral semaglutide tablet, belonging to the GLP-1 receptor agonist class used for appetite regulation, blood sugar control, and medical weight management. It is the first GLP-1 medication available in pill form, offering a non-injection alternative to weekly GLP-1 injections like Ozempic and Wegovy. In Singapore, it is used under doctor supervision as part of a structured weight-loss programme focused on appetite suppression and gradual fat loss.
- Rybelsus contains oral semaglutide. It is the first GLP-1 receptor agonist available as a tablet instead of an injection.
- Works by mimicking the GLP-1 hormone. This helps regulate appetite, increase satiety, and reduce food cravings.
- Taken once daily. It must be taken on an empty stomach with water, followed by a waiting period before eating or taking other medications for proper absorption.
- Supports gradual weight loss. Patients typically experience reduced appetite within weeks and progressive weight reduction over months.
- Dose comes in 3 mg, 7 mg, and 14 mg. Treatment usually starts low and is gradually increased to improve tolerance.
- Effectiveness is moderate compared to injections. Clinical data suggests smaller average weight loss than weekly injectable semaglutide options, but still clinically meaningful results.
- Requires medical supervision. Doctors adjust dosing and monitor side effects to ensure safe and effective use.